SCNX's 1-for-25 and CMND's 1-for-8 Reverse Splits Land Oct. 5 at $0.18, $0.72

For traders and compliance-focused investors, October 5 delivers a rare two-company reverse-split test on Nasdaq. Scienture's 1-for-25 consolidation at $0.18 and Clearmind's 1-for-8 split at $0.72 are mechanical price resets, not value creation, but they reveal which microcaps have enough balance-sheet cushion to avoid the next delisting spiral. With SCNX's $0.34 million quarterly revenue missing estimates by 83% and CMND's market cap at just $730,116, the split ratios are a risk signal as much as a compliance fix.

Two Nasdaq-listed microcap names are moving into post-split territory on the same Monday, October 5, 2026: Clearmind Medicine Inc. (NASDAQ: CMND) with a 1-for-8 reverse split and Scienture Holdings, Inc. (NASDAQ: SCNX) with a more aggressive 1-for-25 reverse split. Neither action changes the company's market capitalization; it simply re-denominates the share count and mechanically raises the per-share price. Clearmind's last trade of $0.72 implies a post-split reference near $5.76, while Scienture's $0.18 close implies about $4.50. Both moves are widely understood as Nasdaq compliance plays aimed at lifting stock prices back above the $1.00 minimum bid requirement.

“

The company reported a narrower-than-expected loss per share of -$0.07 versus a -$0.09 consensus, but revenue came in at just $0.34 million against a $1.96 million estimate, a miss of roughly 83%.

The broader backdrop is a brutal microcap biotech and pharma tape in 2026. Clearmind's 52-week range of $0.71 to $480.00 is extreme even by penny-stock standards, with the company's market capitalization collapsing to $730,116 and its price-to-earnings ratio sitting at -0.02. A 1-for-8 reverse split is therefore cosmetic rather than curative. A simple ratio of 8-to-1 may be insufficient to keep the stock above $1 if legacy selling pressure resumes. Scienture's situation is similar but less extreme on price, with a 52-week high of $2.60 and low of $0.18. The 1-for-25 split was chosen to produce a post-split price near $4.50, yet even that leaves less cushion than the headline suggests if the stock continues to slide.

Scienture's most recent quarterly report, released August 13, 2026, underscores the operational weakness behind the split. The company reported a narrower-than-expected loss per share of -$0.07 versus a -$0.09 consensus, but revenue came in at just $0.34 million against a $1.96 million estimate, a miss of roughly 83%. It carries a low debt-to-equity ratio of 0.15 and adequate liquidity ratios, with current at 3.04 and quick at 2.97, suggesting the split is more about share price than imminent insolvency. Clearmind's balance sheet is lean too, with debt-to-equity of 0.01 and current and quick ratios of 4.31. Its latest quarterly filing, dated September 10, 2026, showed a -$0.57 per-share loss, and no revenue was reported in the aggregator data.

For current shareholders, reverse splits often function as a bearer signal. They do not alter ownership percentage, but they can impair liquidity and invite short sellers. CMND's trading volume on Thursday, October 1 was just 219,393 shares, well below its average of 1,131,579; SCNX volume was 1,900,908, above its average of 1,572,648. In both cases, the post-split float will be smaller and may be harder to trade. The reverse splits also reset per-share historical charts and options strikes, creating artificial gaps that can confuse less sophisticated investors.